ASK PHARM(SZ:002755) 智通财经网·2025-10-20 07:55Core Viewpoint - The announcement highlights the promising results of ASKGENE LIMITED's investigational drug ASKB589 in combination with CAPOX and PD-1 inhibitors for the first-line treatment of advanced gastric cancer, showcasing significant survival benefits and reinforcing the drug's market competitiveness [1] Group 1: Clinical Research Findings - ASKB589, a monoclonal antibody targeting CLDN18.2, demonstrated deep and durable tumor responses and disease control in a Phase Ib/II clinical study for patients with locally advanced, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma [1] - The latest data presented at the ESMO conference confirmed the significant and lasting anti-tumor activity of the ASKB589 combination therapy, marking the first report of overall survival (OS) benefits in advanced first-line gastric cancer patients [1] Group 2: Future Implications - The positive clinical data supports the ongoing pivotal Phase III clinical trials of ASKB589 in combination with chemotherapy and PD-1 inhibitors, enhancing the potential for market competitiveness of the company's product [1]